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Reports from a United States cohort of chronic hemodialysis
patients suggested that weight loss, a decline in pre-dialysis
systolic blood pressure, and decreased serum albumin may
precede death. However, no comparative studies have been
reported in such patients from other countries. Here we
analyzed dynamic changes in these parameters in
hemodialysis patients and included 3593 individuals from 5
Asian countries; 35,146 from 18 European countries; 8649
from Argentina; and 4742 from the United States. In
surviving prevalent patients, these variables appeared to
have notably different dynamics than in patients who died.
While in all populations the interdialytic weight gain, systolic
blood pressure, and serum albumin levels were stable in
surviving patients, these indicators declined starting more
than a year ahead in those who died with the dynamics
similar irrespective of gender and geographic region. In
European patients, C-reactive protein levels were available on
a routine basis and indicated that levels of this acute-phase
protein were low and stable in surviving patients but rose
sharply before death. Thus, relevant fundamental biological
processes start many months before death in the majority of
chronic hemodialysis patients. Longitudinal monitoring of
these dynamics may help to identify patients at risk and aid
the development of an alert system to initiate timely
interventions to improve outcomes.
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Clinical experience shows that chronic hemodialysis (HD)
patients expected to die within weeks share certain character-
istics, such as poor nutrition and weight loss, increased
inflammation, and worsening of cardiovascular status. How-
ever, more subtle changes in other clinical and laboratory
parameters might occur before significant clinical deteriora-
tion becomes apparent. Various risk factors have emerged that
have significant value in predicting the greatly increased
mortality of dialysis patients. However, most of the studies
have focused on single point in time measurements, whereas
the longitudinal trend of surrogate outcome parameters and
the dynamic evolution before death have not been widely
studied.1 Insight into temporal trends of surrogate outcome
indicators are relevant both from a pathophysiological point of
view and for the future development of predictive models,
which might aid the clinician in timely identifying patients at
risk for adverse outcomes.
Recent reports from Renal Research Institute (RRI)
suggested that in chronic HD patients from the United
States, a decline in systolic blood pressure (SBP),2,3 body
weight, and serum albumin levels4 were associated with an
increased mortality risk. It is noteworthy that these dynamic
changes were already apparent months before death and
qualitatively independent of age, gender, and race. These
observations led to the hypothesis that fundamental
biological processes may be operative in the majority of
chronic HD patients weeks and even months before death,
notwithstanding race and gender. However, the observed
patterns of clinical and laboratory parameters before death
may be associated with specific dialysis practices or
environmental factors. As RRI clinics follow similar dialysis
procedures, the relatively homogeneous dialysis practice
pattern renders the testing of this hypothesis difficult.
Therefore, MONDO (MONitoring Dialysis Outcomes), a
multinational consortium of HD databases encompassing
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patient-level data, was founded to further study this aspect.
MONDO allows us to combine HD dialysis databases
containing patient-level data from Asia, North and South
America, and Europe. Because of its outreach, MONDO
encompasses patients of different national, racial, and ethnic
backgrounds. Currently, the MONDO database contains
longitudinal patient-level measurements of key variables
from 4145,000 patients in 25 countries over a time period
of up to 11 years. The MONDO database allowed us to test
the hypothesis that the temporal evolution of certain clinical
and laboratory indicators over several months before death is
comparable among the majority of chronic HD patients,
independent of gender and region of the world. We chose to
study the temporal evolution of indicators of the nutritional,
cardiovascular, and inflammatory domains, namely
interdialytic weight gain (IDWG), SBP, serum albumin, and
C-reactive protein (CRP).
RESULTS
A total of 145,317 HD patients from 25 countries received at
least one in-center HD treatment between January 2000 and
December 2010. Of this number, 41,903 patients died
(Europe: 30,539 deaths (18 countries); Asia: 1809 deaths
(5 countries); South America: 6298 deaths; North America:
3257 deaths). In all, 10,277 incident patients survived X4
years on HD (Europe: 4607; Asia: 1784; South America: 2351;
North America: 1485). Figure 1 presents the flowchart of the
study design. Baseline characteristics of patients who died
and incident patients who survived for X4 years are
presented in Table 1.
Nearly all patients from Europe and South and North
America were prescribed to dialyze thrice weekly. More than
85% of patients were dialyzed three times weekly in
Singapore and Taiwan, whereas 470% were dialyzed twice
weekly in Hong Kong. Dialyzer reuse is a standard practice in
South America, and in most clinics in Singapore and Hong
Kong. All other countries use single-use dialyzers on 490%
of the treatments.
In all regions studied, serum albumin levels dropped
between 0.33 (Asia) and 0.52 (North America) g/dl in the
2 years preceding death in female patients (Figure 2a, left). The
rate of serum albumin decline accelerated before death and
was comparable in Europe and South and North America, and
less pronounced in Asia (Figure 2a, right). The results were
materially identical in male patients (Figure 2b) and compar-
able irrespective of diabetes status (data not shown).
In Europe and North and South America, IDWG declined
significantly before death, whereas the IDWG changes in Asia
were either flat or nonsignificant with wide confidence
intervals (Figures 3a and b).
In female patients from Europe and North and South
America, SBP levels dropped between 7.8 (South America)
and 12.4 (North America) mmHg in the 2 years preceding
death (Figure 4a, left); SBP decline was less pronounced in
patients from Asia. The rate of SBP decline accelerated before
death and was similar in patients from Europe and North and
South America, but less pronounced in Asia (Figure 4a,
right). The results were materially identical in male patients,
although the decline in Asian patients was not significant
(Figure 4b).
CRP levels increased by 20mg/l in the 2 years before
death (Figure 5, left). The rate of CRP increase accelerated
before death and was similar in both genders (Figure 5,
right).
All patients with hemodialysis in-center treatments between 
January 2000 and  December 2010
 145,317
Incident patients
N = 80,033 (55%)
SUM=41,903
SUM=103,414Censored patientsN = 57,287 (72%)
Censored patients with
 4 years of follow-up
N = 10,277* (18%)
Censored patients with
< 4 years of follow-up
N = 47,060* (82%)
Patient cohort for Figures 2–5 is
shown in the red box
Patient cohort for Figures 6–9 is
shown in the blue box
* Because majority of patients did not have blood pressures
recorded in Asia Pacific region before 2006, patients who
survived > 3 years were picked for the Asia Pacific ‘survivor’ cohort
Deaths
N = 22,746 (28%)
Deaths
N = 19,157 (29%)
Censored patients
N = 46,127 (71%)
Prevalent patients
N = 65,284 (45%)
North America: 11,090; South America: 16,632; Europe: 109,524; Asia:8071
Figure 1 | Patient flowchart.
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An analysis of the causes of deaths (cardiovascular disease,
infections, neoplasms, and other) indicated that the majority
of patients in each region died of cardiovascular disease, with
the highest proportion in North America (61%) versus lowest
in Asia (27%). Neoplasms caused the lowest percentage of
deaths in each region. Irrespective of the cause of death, the
dynamics of albumin, IDWG, SBP, and CRP were qualita-
tively comparable before death (Supplementary Figures S1 to
S4 online). In a separate analysis of patients who died of
sudden death, we noted an increase in CRP and a decline in
albumin before death in those patients (data not shown).
Because backward processes (that is, slopes before death)
and forward processes (that is, slopes in surviving patients
looking forward) cannot be compared directly, we conducted
two analyses to elucidate parameter dynamics in survivors
and nonsurvivors. In the first analysis, we selected incident
patients who did not die during the study period and who
survived X4 years on dialysis. We graphed albumin, IDWG,
SBP, and CRP in the first 2 years on dialysis in those patients
to determine if any changes also exist in survivors (Figures
6–9). In the surviving patients, albumin, IDWG, SBP, and
CRP did not appear to change in the first 2 years on HD. In
fact, other than the initial minor increase in albumin, SBP,
CRP, and IDWG remained stable throughout the observation
period (Figures 6–9, left). The first derivatives of the
trajectories also indicated no material change (Figures 6–9,
right). In the second analysis (Supplementary Information
online), we compared patients who survived with patients
with the same vintage who died. Supplementary Figures S5a,
S6a, and S7a online show incident patients who survived the
first 2 years on dialysis (left panels) versus patients who
survived the first 120 days but died between day 121 and end
of 2 years on dialysis (right panels); Supplementary Figure
S8a online delineates CRP in survivors and nonsurvivors in
the same chart. Supplementary Figures S5b, S6b, and S7b
online show patients who survived the first 4 years on dialysis
(left) versus patients who survived the first 2 years on dialysis
but died between year 2 and 4 years (right); Supplementary
Figure S8b online delineates CRP in both survivors
(44 years) and nonsurvivors. These results demonstrate
notable differences in the patterns in the survivors versus
patients who died during the same time period, with
surviving patients generally showing no change, whereas
nonsurvivors followed a declining (CRP rising) trajectory. In
patients who died, the confidence intervals widen as the
number of weeks from start on dialysis increases, because
fewer patients are alive as time progresses.
DISCUSSION
Our study involved 452,000 chronic HD patients from 25
countries and four continents, nearly 42,000 patients who
had died, and B10,000 who had survived 44 years of
dialysis. The main finding is evidence of comparable
temporal evolutions of four key clinical and laboratory
parameters before death. Regardless of geographical location,
IDWG, SBP, and serum albumin started to decline more thanT
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a year before death, with the decline in IDWG and SBP being
less apparent in Asia. In the Fresenius Medical Care (FMC)
Europe network, routine CRP measurements were available,
which showed a steep increase before death.
To the best of our knowledge, this is the first study
showing the dynamic changes of key clinical and laboratory
parameters before death in highly diverse international
cohorts of chronic HD patients. In a previous smaller study
in 2462 maintenance HD patients from Renal Research
Institute (New York, NY), comparable trends for post-HD
weight and serum albumin were shown.4 However, given the
large variability of background mortality and treatment
patterns throughout the world,5–8 this study analyzed
whether these trends were also apparent from a global
perspective. Notably, most parameters assessed here started
to deteriorate more than 1 year before death. Interestingly, a
recent study indicated that functional status of HD patients
remained stable until 1 month before death.9 This temporal
difference suggests that subtle changes in physiological and
laboratory parameters may herald clinical deterioration in
dialysis patients, possibly at a stage that is amenable to
intervention.
The decline in serum albumin was apparent at an earlier
stage in this study as compared with the previous RRI study.
However, this may be because of differences in statistical
methodology between both studies. Whereas the previous
study was based on linear mixed models, using linear spline
functions with a knot point 12 weeks before death, this study
looked at all observations 104 weeks before death in a
continuous manner.10 The stable albumin levels in incident
surviving patients observed by us can be compared with
results from the Hemodialysis (HEMO) trial, where during
the first 3 years of follow-up mean serum albumin levels
declined by 0.21 g/dl.11 However, in contrast to our study, the
HEMO trial enrolled prevalent patients with a vintage of
3.7±4.4 years, rendering a direct comparison with our
results difficult.
The pathophysiological mechanisms underlying these
dynamics cannot be directly deduced from the present
observational data. The four parameters were chosen because
they may reflect changes in three key domains, namely
cardiovascular function, nutrition, and inflammation, and
because most of these indicators (except CRP) are readily
available and are used in daily clinical practice.
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The decline in SBP may reflect deterioration in cardio-
vascular function,3 such as reduced cardiac output over time.
The reduction in IDWG may reflect poorer appetite and
diminished food intake.12 In this respect, it may be more
sensitive than post-HD weight, which usually represents the
prescribed target weight. Importantly, body composition may
change significantly in the absence of body weight changes.
For instance, despite a decline in lean body mass, body
weight may remain stable because of a concurrent increase in
extracellular volume if post-HD target weight is not adjusted
accordingly. The decline in IDWG and SBP before death is
likely a reflection of ‘reverse epidemiology,’13 and cannot be
used as an argument against the importance of blood
pressure control and meticulous attention to sodium and
fluid volume restriction in dialysis patients. Indeed, several
studies have shown a relationship between high IDWG (as
well as fluid overload) and hypertension and mortality.14–16
Serum albumin, a composite marker of nutrition and
inflammation, and CRP are strong predictors of out-
come.17–19 The increase in CRP and the decline in the other
three studied parameters occurred largely independently of
age, gender, race, or region of the world (data on age and race
not shown). Notable exceptions were the absence of declines
in SBP in male, and in IDWG in both male and female Asian
patients. The fact that SBP declined before death in all
populations except in male HD patients from Asia is
remarkable, and one may speculate that fluid overload is
more prevalent in Asian patients close to death;
unfortunately, this observation cannot be explained by the
present data. It remains to be established whether environ-
mental, treatment-related, genetic, and/or cardiac factors are
involved in this phenomenon;15,20–22 the relatively small
number of patients (787 males) may also be a factor. Diffe-
rent clinical practices related to target weight determination
and monitoring may vary among the patients studied,
resulting in different blood pressure dynamics, particularly
for malnourished patients whose target weight is not adjusted
timely to their body weight.
Pre- and post-dialysis weights are only recorded once a
month in the FMC Asia-Pacific network, and hence detailed
information on IDWG may be missed. Studies in Southeast
Asian populations living in the United States may provide
important additional insights. The substantially higher SBP
seen in both surviving and nonsurviving US patients
compared with the other regions is impressive and deserves
further investigation. We hypothesize that differences in fluid
and anemia management and antihypertensive therapy may
contribute to this observation.23
Analysis of trajectories of all factors measured before death
by cause of death revealed no notable differences between
patients dying from cardiovascular disease, infections, or
neoplasms. Neoplasms appear to be associated with the most
striking dynamic trends in the four parameters studied.
Declines in albumin and increases in CRP were also observed
in patients who died of sudden death, consistent with prior
findings.24
This international study may contribute to the under-
standing of the pathophysiological phenomena occurring
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Figure 4 |Mean pre-hemodialysis (pre-HD) systolic blood
pressure (SBP) and 95% confidence intervals. (a) Mean pre-
hemodialysis (pre-HD) systolic blood pressure (SBP) and 95%
confidence intervals in female patients in the 104 weeks before
death. The left panels show estimates of the partially conditional
means with 95% confidence intervals, and the right panels show
estimates of rate of change trajectories with 95% confidence
intervals. (b) Mean pre-HD SBP and 95% confidence intervals in male
patients in the 104 weeks before death.
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before death in this highly vulnerable group of patients. The
main message for the clinical practitioner is that the temporal
evolutions of albumin, SBP, IDWG, and CPR are as
important to follow as their absolute levels. This insight
should also serve as a wake-up call for dialysis providers, as
they may have to put information systems in place that allow
the physicians to not only follow absolute levels of variables
but also their dynamics. Although a decline in albumin levels
or rises in CRP usually alerts health-care providers, a
consistent and unintended decline of SBP by more than
2–5mmHg per quarter or IDWG drop by40.2% per quarter
may go unnoticed. On an operational level, the identification
of temporal patterns can be supported by patient reports that
depict both absolute levels and trends of variables. Moreover,
the results of our study offer guidance for the development of
predictive models. We speculate that it might be possible to
construct multivariate algorithms by combining IDWG, SBP,
and serum albumin levels that may be more predictive of the
death risk than each individual parameter. Such models may
appreciate even subtle intraindividual dynamics, such as mild
drops of SBP over the course of months and a decline of
serum albumin even within the normal range, which are
likely to escape notice in a busy clinical setting. Paradoxically,
some of these changes of key indicators may be welcomed as
the result of successful interventions. Of course, lower IDWG
may also be the outcome of successful fluid counseling and
also of salt restriction, and SBP decline may indicate better
blood pressure control. However, as our data show, these
changes may also be ominous signs, and to differentiate these
possibilities requires a keen clinical assessment of the patient.
Whether or not ‘alert systems’ can trigger more timely and
cost-effective interventions and improve clinical outcomes
has to be addressed in future prospective trials. These alert
systems can be based on various statistical methodologies and
use a severity index to highlight patients at higher risk of
death requiring an intervention. However, there is little doubt
that understanding changes preceding death by many months
is indispensable for the development of predictive models.
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A potential limitation of the study is that a majority of the
patients studied are treated in FMC clinics. On the other
hand, in Europe, patients from a different dialysis provider,
KfH Germany, comprised a large component but provided
similar results (not shown separately). Another limitation is
the overrepresentation of patients from Europe and South
America. We tried to address this issue by analyzing the data
from each region separately. The current analysis is limited to
four parameters only, which reflect cardiovascular, nutri-
tional, and inflammatory domains. Future studies will extend
these analyses to other indicators, including measures of
cardiac function and body composition.
In conclusion, the temporal evolution of key clinical and
laboratory indicators before death was found to be compar-
able in large international cohorts of chronic HD patients
from four continents, with some exceptions in Asia. These
findings raise the possibility that similar biological processes
are operative in the months before death irrespective of
gender, race, and region of the world. These findings may
contribute to improved understanding of the factors leading
to poor outcome in dialysis patients and aid the development
of risk prediction models that may facilitate timely interven-
tions and hopefully improve outcomes.
MATERIALS AND METHODS
Participants and study design
In this retrospective cohort study, we identified all chronic HD
patients from 25 countries in 5 continents treated in clinics of FMC
from Europe (17 countries), FMC Latin America (Argentina only),
FMC Asia-Pacific (South East Asia and Australia, 5 countries), Renal
Research Institute (USA), and the Kuratorium fu¨r Dialyse und
Nierentransplantation e.V. (KfH, Germany) between 1 January 2000
and 31 December 2010 (‘study period’). The data from these
provider databases were aggregated into continents: FMC Europe
and KfH Germany data are titled ‘Europe’; FMC Latin America data
are titled ‘South America’; FMC Asia-Pacific data are titled ‘Asia’;
and data from RRI are represented as ‘North America.’
Patients with at least one HD in-center treatment during the
study period were stratified into incident (patients with first
treatment recorded within 90 days of first ever dialysis) and
prevalent. We conducted two separate analyses: the first looked at
incident and prevalent patients who died during the study period
(N¼ 41,903), and the second looked at incident patients who did
not die during the study period and survived 44 years on dialysis
(‘censored’ patients) (N¼ 10,277). These two cohorts were chosen
to assure that the two analyzed patient cohorts (survivors and
nonsurvivors) did not overlap. Figure 1 presents the flowchart of the
study design. Additional results are presented in Supplementary
Information online, where we separate the dynamics before death by
cause of death and compare the patients who survived with those
who died with the same vintage. For the figures, only the continents
with 4250 patients were included (thus excluding Australia).
Furthermore, all figures include only continents with450 weeks of
available observations with 410 patients in each week.
Data flow and analysis
In most databases, clinical data were transferred manually from the
respective data sheets into a master database. Multiple levels of
internal quality control measures were in place to guarantee data
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consistency and validity. In most European clinics and all of
the RRI clinics, laboratory data were directly imported electronically
from the clinical laboratories. KfH (Germany) data were analyzed
locally by statisticians working with this particular network; all other
data were analyzed centrally at the Department of Statistics and
Applied Probability, University of California, Santa Barbara (Santa
Barbara, CA). The same validated program codes were used by all
statisticians.
Clinical parameters
Pre- and post HD body weight was measured using scales
calibrated according to the respective national standards. IDWG in
percent of post-HD body weight was calculated as the difference
between pre-HD weight and the preceding post-HD weight divided
by the preceding post-HD weight. In the European and North
American data, SBP and IDWG are available for each dialysis
session; in Asia and South America these data were available
monthly. Of note, for Asia and South America, this meant that
postdialysis weight from the previous month was used in calculation
of IDWG. SBP was assessed by automated devices in all patients in
North America, Asia, and Europe. Manual measurement of
SBP was the standard procedure in South America. In all databases,
SBP was measured with patients at rest in a supine or sitting
position.
Laboratory analysis
In most European clinics and all of the RRI clinics, laboratory data
were directly imported electronically from the clinical laboratories.
The MONDO database compiles information on laboratory assays
used. Serum albumin was measured by nephelometry in KfH
(Germany) clinics and by the bromocresol green (BCG) method in
all European clinics (except for Portugal), most Asian clinics,
South America, and the United States. Both methods are calibrated
to the international standard ERM DA 470k/IFCC. The bromocresol
purple (BCP) method was used in Portugal and some HD clinics in
Asia. To ensure comparability between the two methods, BCP
measurements were transformed to BCG values using a published
formula (concentrations in g/dl):25 AlbuminBCG¼AlbuminBCP
þ 0.55. Serum albumin levels were measured at regular intervals,
ranging from monthly to quarterly. CRP was measured routinely only
in FMC Europe clinics.
Statistical analysis
For descriptive purposes, means and s.d. of continuous variables and
percentages for categorical variables are presented. For the analysis
of the variables of interest (IDWG, SBP, CRP, and albumin), we
considered the backward processes that start at death and go
backward in time.10 Y(u) is denoted as the backward process for a
patient u weeks (or months) before death, and T as the survival time
of this patient from the initiation of dialysis. We were interested in
estimating the partially conditional mean E(Y(u) | T4u) for a
period of 2 years before death.26 The partially conditional mean
E(Y(u) | T4u) represents the expectation of the backward process u
weeks before death conditional on the patient having survived
longer than u weeks. For weekly measurements, the 2-year period
was divided into 104 weeks. For the fixed 1pup104 weeks, we
estimated E(Y(u) | T4u) by the average measurements among
patients who survived longer than u weeks. The weekly (or monthly)
estimates of partially conditional means were rough. To further
investigate the trend of the partially conditional means and their
trajectories before death, we fitted the estimated weekly partially
conditional means using quintic splines and estimated the
trajectories of the first derivatives (‘velocity’), which represent the
rate of change of the variable. The R package ASSIST (R Foundation
for Statistical Computing, Vienna, Austria) was used to fit the
quintic spline where the smoothing parameter was selected by the
generalized maximum likelihood method. Bootstrap confidence
intervals were constructed as described by Wang.27
Similar spline functions were fitted in the forward analysis
looking at all incident patients who survived for 44 years: data for
IDWG, albumin, CRP, and SBP were analyzed over a period of 2
years (104 weeks) from the start of dialysis. This cohort was chosen
to avoid overlap with the backward process. Similar methodology
was applied to figures shown in Supplementary Information online.
All computations were made with R statistics software system,
version 2.11.1 (R Foundation for Statistical Computing).28
DISCLOSURE
PK and NWL hold stock in Fresenius Medical Care. The remaining
authors declared no competing interests.
ACKNOWLEDGMENTS
We thank all the kidney centers in the different countries contributing
to this analysis. We also thank Erika Schuh, Paola Carioni, Peter
Kaufmann, Marzio Alunni, and Claudia Amato of the FMC Europe
NephroCare Team for putting together the data from patients treated
in FMC European countries.
SUPPLEMENTARY MATERIAL
Supplementary Information: Supplementary information contains
additional figures that separate dynamics of albumin, pre-dialysis
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versus those who died over the same vintage (Supplementary
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